PetMed 13D Filing: SilverCape Proposes $3 Take-Private Bid

The news

SilverCape Investments Limited and Peter Kennedy filed Amendment No. 2 to their Schedule 13D on PetMed Express, Inc. on June 29, 2026. The 13D filing disclosed that SilverCape had sent a letter that day proposing to take PetMed private by acquiring all of its outstanding common stock for $3.00 per share in cash.

The reporting persons beneficially owned 2,579,696 shares, or 12.07% of the class, based on 21,365,782 shares outstanding as of May 22, 2026. Kennedy shares voting and dispositive power over the SilverCape position.

The proposal is non-binding. According to Item 4, it depends on due diligence and the negotiation and signing of a definitive agreement, and SilverCape reserved the right to modify or withdraw it at any time. The letter and an accompanying press release were attached as Exhibit 99.2.

Our analysis

A 13D filing that converts a passive-looking stake into a buyout offer changes the dynamics for a board. SilverCape is not an outside bidder approaching cold; it already owns about one-eighth of the company, which gives it a voting base, inside knowledge of the shareholder register and a credible platform to press its case publicly.

The math is simple to check from the filing. At $3.00 per share across 21,365,782 shares, the proposal values PetMed’s equity at roughly $64 million. For SilverCape, buying the remaining 87.93% would cost about $56 million on our arithmetic.

The non-binding nature matters. Without a financing commitment or a signed agreement, the board’s typical response would be to form a special committee of independent directors, hire advisers and evaluate the offer against standalone plans and other potential bidders. An insider-led take-private also brings heightened scrutiny of process because the bidder has an information advantage over other shareholders.

The 13D amendment format also matters for other holders. Each material change in SilverCape’s plans, such as a revised price, financing commitments or a decision to withdraw, must be reported in a further amendment. That gives the market a running record of the bidder’s intentions, separate from whatever the company itself discloses.

Publishing the letter alongside a press release signals that SilverCape wanted shareholders and the market to see the offer, not just the board. That is a common activist campaign tactic: by putting a number in public, a bidder anchors the conversation and puts pressure on directors to engage.

Room for disagreement

One view is that a cash offer from a large shareholder offers a clean exit for investors in a company whose market value had fallen to a level where a $3.00 bid was meaningful. Another is that a significant holder proposing a buyout at a low absolute valuation could capture value that belongs to all shareholders, particularly if the business has assets or turnaround potential the bid does not reflect. Without the company’s own projections, which typically surface only in a proxy statement if a deal proceeds, outsiders cannot settle that question.

There is also uncertainty about SilverCape’s ability to close. The filing does not describe financing sources, and the right to withdraw at any time means the proposal could fade if diligence disappoints.

For PetMed’s directors, the duty is to evaluate the proposal on its merits for all shareholders. That usually means comparing the $3.00 offer with the company’s standalone plan, testing interest from other potential buyers, and negotiating price and terms if engagement makes sense. A board can also reject a non-binding proposal outright if it believes the price undervalues the company, which would leave SilverCape to decide whether to raise its offer, seek board seats or step back.

What to watch

Watch for PetMed’s response, including whether it forms a special committee; further 13D amendments disclosing financing, revised terms or additional share purchases; any competing proposals; and whether SilverCape escalates with board nominations if talks stall.